Infantile Spasms Therapeutics Market By Drug Type (Corticosteroids, Adrenocorticotropic Hormones (ACTH) , Antiepileptic Drugs (AEDs) , Others) , By Route of Administration (Oral, Parenteral) By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Infantile Spasms Therapeutics Market
The infantile spasms therapeutics market was valued at $162.0 million in 2023 and is projected to reach $223.4 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.
The infantile spasms therapeutics market focuses on the treatment of infantile spasms, which is a rare, severe form of epilepsy that occurs in infants between the age of 3 and 12 months. The primary treatment approaches comprise combinations of hormonal therapies, antiepileptic drugs (AEDs), and dietary interventions. Surgical interventions are considered during cases of intractable infantile spasms.
The growth of the infantile spasms therapeutics market is significantly driven by increase in awareness regarding the prevalence of neurological disorders and improvement in diagnostic capabilities. In addition, innovations in drug discovery and development have enhanced the potential of therapeutics, thereby augmenting the growth of the market. A prominent trend poised to dominate the market is the application of gene therapy & precision medicine to enhance the efficacy of treatment and improve patient outcomes. The incorporation of unique anatomical and genetic attributes of each patient via these ingenious methods is expected to reduce the occurrence of spasms in infants.
However, the high costs of therapeutics and potential side effects of different drugs deter several individuals from undergoing the treatment, restraining the growth of the infantile spasms therapeutics market. Moreover, challenges pertaining to diagnosis at early stages hamper the market growth notably. On the contrary, upsurge in funding & investments by governments or associated institutions is projected to fuel explorations in the field of infantile spasms therapeutics and present lucrative opportunities for the expansion of the market. For instance, CURE Epilepsy—an American non-profit research organization—awarded funds to Dr. David Auerbach at the Upstate Medical University in New York on December 2023 to investigate the role of cardiac biomarkers in epilepsy.
Segment ReviewThe infantile spasms therapeutics market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is divided into corticosteroids, adrenocorticotropic hormones (ACTH), antiepileptic drugs (AEDs), and others. Depending on route of administration, it is bifurcated into oral and parenteral. By distribution channel, it is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key FindingsOn the basis of drug type, the antiepileptic drugs (AEDs) segment is expected to dominate the market during the forecast period.
Depending on route of administration, the parenteral segment is projected to garner a high market share by 2033.
By distribution channel, the drug stores & retail pharmacies segment is anticipated to acquire a high share of the market throughout the forecast period.Region wise, North America is predicted to be the highest revenue generator by 2033.
Competition AnalysisThe major players in the global infantile spasms therapeutics market include Mallinckrodt Pharmaceuticals, H. Lundbeck A/S, Pfizer Inc., UCB Pharma S.A., Jazz Pharmaceuticals, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and AbbVie Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Key Market SegmentsBy Drug TypeCorticosteroids
Adrenocorticotropic Hormones (ACTH)
Antiepileptic Drugs (AEDs)
Others
By Route Of AdministrationOral
Parenteral
By Distribution ChannelHospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By RegionNorth America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market PlayersMallinckrodt Pharmaceuticals
H. Lundbeck A/S
Pfizer Inc.
UCB Pharma S.A.
Jazz Pharmaceuticals, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Viatris Inc.
AbbVie Inc.